Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
Utkarsh Goel(Cleveland Clinic), Shaji Kumar(Mayo Clinic), Francis K. Buadi, Morie A. Gertz(Medical University of South Carolina), Nelson Leung(WinnMed), Robert A. Kyle(Mayo Clinic), Prashant Kapoor, Amie Fonder, Moritz Binder(Mayo Clinic in Arizona), Yi L. Hwa, Rahma Warsame, Charalampos Charalampous(Mayo Clinic), S. Vincent Rajkumar(WinnMed), Wilson I. Gonsalves(Mayo Clinic in Arizona), Taxiarchis Kourelis(Mayo Clinic in Arizona), Martha Q. Lacy(Mayo Clinic), Yi Lin, Suzanne R. Hayman, Angela Dispenzieri(Mayo Clinic), Miriam Hobbs, David Dingli
Cited by 6
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k